Literature DB >> 30044358

Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition.

Dan Turner1, Frank M Ruemmele2, Esther Orlanski-Meyer1, Anne M Griffiths3, Javier Martin de Carpi4, Jiri Bronsky5, Gabor Veres6, Marina Aloi7, Caterina Strisciuglio8, Christian P Braegger9, Amit Assa10, Claudio Romano11, Séamus Hussey12, Michael Stanton13, Mikko Pakarinen14, Lissy de Ridder15, Konstantinos H Katsanos16, Nick Croft17, Víctor Manuel Navas-López18, David C Wilson19, Sally Lawrence20, Richard K Russell21.   

Abstract

BACKGROUND AND AIM: Acute severe colitis (ASC) is one of the few emergencies in pediatric gastroenterology. Tight monitoring and timely medical and surgical interventions may improve outcomes and minimize morbidity and mortality. We aimed to standardize daily treatment of ASC in children through detailed recommendations and practice points which are based on a systematic review of the literature and consensus of experts.
METHODS: These guidelines are a joint effort of the European Crohn's and Colitis Organization (ECCO) and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Fifteen predefined questions were addressed by working subgroups. An iterative consensus process, including 2 face-to-face meetings, was followed by voting of the national representatives of ECCO and all members of the Paediatric Inflammatory Bowel Disease (IBD) Porto group of ESPGHAN (43 voting experts).
RESULTS: A total of 24 recommendations and 43 practice points were endorsed with a consensus rate of at least 91% regarding diagnosis, monitoring, and management of ASC in children. A summary flowchart is presented based on daily scoring of the Paediatric Ulcerative Colitis Activity Index. Several topics have been altered since the previous 2011 guidelines and from those published in adults. DISCUSSION: These guidelines standardize the management of ASC in children in an attempt to optimize outcomes of this intensive clinical scenario.

Entities:  

Mesh:

Year:  2018        PMID: 30044358     DOI: 10.1097/MPG.0000000000002036

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   3.288


  29 in total

1.  Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.

Authors:  Jessica Breton; Arthur Kastl; Maire A Conrad; Robert N Baldassano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-08

Review 2.  Acute Infectious Gastroenteritis in Infancy and Childhood.

Authors:  Carsten Posovszky; Stephan Buderus; Martin Classen; Burkhard Lawrenz; Klaus-Michael Keller; Sibylle Koletzko
Journal:  Dtsch Arztebl Int       Date:  2020-09-11       Impact factor: 5.594

3.  Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.

Authors:  Jeffrey S Hyams; Sonia Davis Thomas; Nathan Gotman; Yael Haberman; Rebekah Karns; Melanie Schirmer; Angela Mo; David R Mack; Brendan Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; David J Keljo; James Markowitz; Susan S Baker; Joel Rosh; Robert N Baldassano; Ashish Patel; Marian Pfefferkorn; Anthony Otley; Melvin Heyman; Joshua Noe; Maria Oliva-Hemker; Paul A Rufo; Jennifer Strople; David Ziring; Stephen L Guthery; Boris Sudel; Keith Benkov; Prateek Wali; Dedrick Moulton; Jonathan Evans; Michael D Kappelman; M Alison Marquis; Francisco A Sylvester; Margaret H Collins; Suresh Venkateswaran; Marla Dubinsky; Vin Tangpricha; Krista L Spada; Bradley Saul; Jessie Wang; Jose Serrano; Kevin Hommel; Urko M Marigorta; Greg Gibson; Ramnik J Xavier; Subra Kugathasan; Thomas Walters; Lee A Denson
Journal:  Lancet       Date:  2019-03-29       Impact factor: 79.321

4.  Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.

Authors:  Jessica Breton; Arthur Kastl; Natalie Hoffmann; Rachel Rogers; Andrew B Grossman; Petar Mamula; Judith R Kelsen; Robert N Baldassano; Lindsey Albenberg
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

5.  Growth Delay in Inflammatory Bowel Diseases: The Importance of Surgery.

Authors:  Rogério Serafim Parra; José Joaquim Ribeiro da Rocha; Omar Féres
Journal:  Dig Dis Sci       Date:  2021-06-28       Impact factor: 3.199

6.  Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.

Authors:  Hillary Moore; Pasquale Dolce; Nina Devas; Robert Baldassano; Massimo Martinelli
Journal:  United European Gastroenterol J       Date:  2020-03-12       Impact factor: 4.623

7.  Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study.

Authors:  Matteo Bramuzzo; Serena Arrigo; Claudio Romano; Maria Chiara Filardi; Paolo Lionetti; Anna Agrusti; Valeria Dipasquale; Monica Paci; Giovanna Zuin; Marina Aloi; Caterina Strisciuglio; Erasmo Miele; Maria Pastore; Stefano Martelossi; Patrizia Alvisi
Journal:  United European Gastroenterol J       Date:  2019-04-25       Impact factor: 4.623

8.  Renal Impairment Associated With Trimethoprim-Sulfamethoxazole Use in the Pediatric Population.

Authors:  Caroline M Sierra; Yen Tran; Lacey Oana; Khaled Bahjri
Journal:  J Pediatr Pharmacol Ther       Date:  2022-09-26

Review 9.  Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor.

Authors:  Lorraine Stallard; Séamus Hussey
Journal:  Front Pediatr       Date:  2021-06-23       Impact factor: 3.418

10.  A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.

Authors:  Hsuan Ping Chang; Valentina Shakhnovich; Adam Frymoyer; Ryan Sol Funk; Mara L Becker; K T Park; Dhaval K Shah
Journal:  Br J Clin Pharmacol       Date:  2021-07-19       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.